
Christopher A Green

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3345777/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. Thorax, 2022, 77, 259-267.	5.6	34
2	Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. MSphere, 2022, 7, e0067421.	2.9	5
3	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	13.7	161
4	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 546.	7.4	229
5	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet Digital Health, 2022, 4, e220-e234.	12.3	20
6	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial Journal of Infection, 2022, 84, 795-813.	3.3	43
7	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 2022, 77, 606-615.	5.6	24
8	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 2022, 9, ofac179.	0.9	10
9	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respiratory Medicine,the, 2022, 10, 1049-1060.	10.7	24
10	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	27.0	8,063
11	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
12	COVIDâ€19: medical students in clinical research. Clinical Teacher, 2021, 18, 79-81.	0.8	6
13	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
14	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology, 2021, 6, .	11.9	161
15	The journey towards safely restarting faecal microbiota transplantation services in the UK during the COVID-19 era. Lancet Microbe, The, 2021, 2, e133-e134.	7.3	5
16	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 349-359.	10.7	161
17	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
18	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 1637-1645.	13.7	1,374

CHRISTOPHER A GREEN

#	Article	IF	CITATIONS
19	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet, The, 2021, 397, 2049-2059.	13.7	391
20	Multi-modality detection of SARS-CoV-2 in faecal donor samples for transplantation and in asymptomatic emergency surgical admissions. F1000Research, 2021, 10, 373.	1.6	5
21	The Volunteers in Research programme: supporting COVID-19 research and improving medical training in parallel. Clinical Medicine, 2021, 21, 182-188.	1.9	5
22	Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC Health Services Research, 2021, 21, 566.	2.2	22
23	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 773-785.	10.7	78
24	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	13.7	110
25	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatology, The, 2021, 3, e498-e506.	3.9	58
26	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	7.3	216
27	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	13.7	430
28	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet, The, 2021, 398, 1037-1038.	13.7	75
29	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	12.4	80
30	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
31	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
32	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	13.7	519
33	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
34	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	13.7	569
35	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ, The, 2020, 370, m3339.	6.0	779
36	COVID-19: time for a bold new strategy for medical education. Medical Education Online, 2020, 25, 1764741.	2.6	43

CHRISTOPHER A GREEN

#	Article	IF	CITATIONS
37	Towards personalized guidelines: using machine-learning algorithms to guide antimicrobial selection. Journal of Antimicrobial Chemotherapy, 2020, 75, 2677-2680.	3.0	23
38	Priorities for developing respiratory syncytial virus vaccines in different target populations. Science Translational Medicine, 2020, 12, .	12.4	30
39	Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward. The Lancet Gastroenterology and Hepatology, 2020, 5, 531.	8.1	29
40	Vaccination against Respiratory Syncytial Virus. Interdisciplinary Topics in Gerontology and Geriatrics, 2020, 43, 182-192.	2.6	6
41	Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, The, 2020, 369, m1985.	6.0	2,474
42	Case Report: Subarachnoid Hemorrhage and Eosinophilic Meningitis due to Disseminated Fascioliasis. American Journal of Tropical Medicine and Hygiene, 2020, 102, 574-577.	1.4	2
43	Respiratory syncytial virus: diagnosis, prevention and management. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611986579.	1.8	65
44	Airway response to respiratory syncytial virus has incidental antibacterial effects. Nature Communications, 2019, 10, 2218.	12.8	30
45	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. Journal of Infection, 2019, 78, 382-392.	3.3	42
46	Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine, 2018, 36, 6988-6994.	3.8	0
47	Humoral and cellular immunity to RSV in infants, children and adults. Vaccine, 2018, 36, 6183-6190.	3.8	20
48	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Tropical Diseases, 2016, 10, e0004926.	3.0	67
49	Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Therapeutic Advances in Infectious Disease, 2016, 3, 63-71.	1.8	49
50	RSV vaccine use \hat{a} €" the missing data. Expert Review of Vaccines, 2016, 15, 149-152.	4.4	17
51	Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Archives of Disease in Childhood, 2016, 101, 140-146.	1.9	157
52	Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open, 2015, 5, e008748.	1.9	49
53	Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science Translational Medicine, 2015, 7, 300ra126.	12.4	109
54	A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. Journal of Infection, 2015, 71, 326-337.	3.3	40

#	Article	IF	CITATIONS
55	Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Archives of Disease in Childhood, 2013, 98, 248-251.	1.9	18
56	CHANGING ANTIBIOTIC PROPHYLAXIS FOR TRANSRECTAL ULTRASOUNDâ€GUIDED PROSTATE BIOPSIES: ARE WE PUTTING OUR PATIENTS AT RISK?. BJU International, 2011, 108, E155.	2.5	0
57	Chest radiography findings in adults with pandemic H1N1 2009 influenza. British Journal of Radiology, 2010, 83, 499-504.	2.2	14
58	Swine flu: a Birmingham experience. Clinical Medicine, 2009, 9, 534-538.	1.9	22
59	A T-cell-dependent humoral immune response is preserved during the administration of the nerve agent pre-treatment pyridostigmine bromide in a murine model. International Immunopharmacology, 2005, 5, 525-540.	3.8	2
60	Inherited metabolic diseases in the sudden infant death syndrome Archives of Disease in Childhood, 1991, 66, 1315-1317.	1.9	35
61	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients, SSRN Electronic Journal, 0,	0.4	56